Lilly to Present New Data on Foundayo, Retatrutide, and EloraTZP at EASD 2026
Eli Lilly will present new cardiometabolic data at EASD 2026, including pivotal Phase 3 results for retatrutide, the largest and longest study of Foundayo in type 2 diabetes, and Phase 2 data for eloraTZP.
By Eli Lilly and Company






